Your browser doesn't support javascript.
loading
The efficacy and safety of coenzyme Q10 in preventing the progression of early Parkinson's disease: A meta-analysis
Acta Medica Philippina ; : 100-104, 2017.
Artigo em Inglês | WPRIM | ID: wpr-633391
ABSTRACT

INTRODUCTION:

Coenzyme Q10, also known as Ubiquinone, is a substance now being used as a dietary supplement in many countries including the Philippines. It has also been the focus of several researches as treatment for several diseases including Parkinson's Disease. Several studies have shown that Coenzyme Q10 inhibits mitochondrial dysfunction in Parkinson's Disease, hence delaying its progression.

OBJECTIVES:

The objective of this study is to assess and summarize the available evidence on the efficacy and safety of Coenzyme Q10 administration in the prevention of the progression of early Parkinson's Disease.

METHODS:

This is meta-analysis of randomized controlled trials on the use of Coenzyme Q10 in Parkinson's Disease. A literature search in several databases was conducted for relevant studies. Three randomized controlled trials met the inclusion criteria. The efficacy of Coenzyme Q10 were measured using the total and the component scores of the Unified Parkinson Disease Rating Scale on follow-up. On the other hand, safety were measured using the withdrawal rate and the associated adverse reactions during the therapy of CoQ10. The Review Manager Software was utilized for the meta-analysis.

RESULTS:

Compared to Placebo, treatment of CoQ10 did not show any significant difference in the mean scores of the UPDRS mental and ADL scores. Interestingly, the UPDRS motor score showed a significant difference between Coenzyme Q10 and placebo, but no significant difference when a subgroup analysis between high-dose (-4.03 [-15.07-7.01], p-value 0.47, I2 67%, P for heterogeneity 0.08) and low-dose Coenzyme Q10 (0.53 [-0.89-1.94], p-value 0.47, I2 34%, P for heterogeneity 0.22) was done. Overall, there was no significant difference in the total UPDRS score (0.68 [-0.61-1.97], p-value 0.30, I2 0%, P for heterogeneity 0.70). The anxiety, back pain, headache, sore throat, nausea, dizziness and constipation.

CONCLUSION:

Contrary to some animal and human studies, this meta-analysis showed that the use of CoQ10 results to non-significant improvement in all components of the UPDRS scores as opposed to placebo. However, the use of CoQ10 is tolerated and seems to be safe but further studies are needed to validate this finding.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Doença de Parkinson / Faringite / Vertigem / Ubiquinona / Dor nas Costas / Constipação Intestinal / Tontura / Cefaleia / Rigidez Muscular Tipo de estudo: Ensaio Clínico Controlado / Revisões Sistemáticas Avaliadas Idioma: Inglês Revista: Acta Medica Philippina Ano de publicação: 2017 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Doença de Parkinson / Faringite / Vertigem / Ubiquinona / Dor nas Costas / Constipação Intestinal / Tontura / Cefaleia / Rigidez Muscular Tipo de estudo: Ensaio Clínico Controlado / Revisões Sistemáticas Avaliadas Idioma: Inglês Revista: Acta Medica Philippina Ano de publicação: 2017 Tipo de documento: Artigo